When is targeted therapy recommended for myelofibrosis?

Myelofibrosis affects the bone marrow and can cause low blood counts, an enlarged spleen, tiredness, night sweats, weight loss, bone discomfort, or a feeling of fullness after eating. The haematology team reviews symptoms, examination findings, blood counts, spleen size, marrow results, and molecular information when choosing treatment. A targeted medicine may reduce signals that drive abnormal blood-cell production and inflammation. It may improve symptoms without removing every abnormal cell, so ongoing monitoring remains necessary. Other approaches may be discussed if risk, symptoms, or treatment response changes.

Ask which symptom or disease feature the medicine is intended to address and how quickly improvement will be assessed. Discuss blood-count monitoring, infection precautions, bleeding symptoms, and what to do about missed doses. Tell the team about previous clots, bleeding, infections, liver or kidney problems, and all medicines. Ask whether spleen size and blood counts will be checked at each review. Read more about [Myelofibrosis](/conditions/myelofibrosis/) and [Targeted Therapy](/treatments/systemic-therapy/targeted-therapy/).

Contact your haematology team promptly for fever, worsening tiredness, unusual bruising or bleeding, increasing abdominal fullness, severe dizziness, or new breathlessness. Seek urgent help for heavy bleeding, sudden chest pain, severe breathlessness, fainting, or sudden weakness on one side. Keep taking treatment as prescribed unless the team gives different instructions.

What is driving my symptoms or blood-count changes? Which target does this medicine affect? How will we assess spleen size and symptom response? What should happen if my blood counts fall?